ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. founded in 2015 and is based in Winston-Salem, North Carolina.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PROK	$1.80	-2.70%	1.05M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PROK	$1.80	-2.7%	1.05M
3
4
5
6

PROK

Get ProKidney Corp. Data in Excel

Get ProKidney Corp. Data in Excel